DOD Prostate Cancer Research Program opportunities

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The FY18 Defense Appropriations Act provides $100 million to the Department of Defense Prostate Cancer Research Program to support innovative, high-impact prostate cancer research.

FY18 PCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov.

Applications submitted to the FY18 PCRP must addresses one or more of the Overarching Challenges (revised for FY18):

  • Develop treatments that improve outcomes for men with lethal prostate cancer

  • Reduce lethal prostate cancer in African Americans, Veterans, and other high-risk populations

  • Define the biology of lethal prostate cancer to reduce death

  • Improve the quality of life for survivors of prostate cancer

http://cdmrp.army.mil/funding/pcrp


Health Disparity Research Award

Letter of Intent due Sept. 20


Health Disparity Scholar Award

Letter of Intent due Sept. 20


A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal at https://eBRAP.org prior to the pre-application deadline.

All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.

YOU MAY BE INTERESTED IN

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login